Log in

Start Your Membership Now

People with major depressive disorder (MDD) who received a personalized antidepressant selected using a web-based clinical decision-support system were less likely to discontinue treatment within eight weeks. The discontinuation rate was 17% for those who received a personalized antidepressant prescription compared to 27% for those who received usual care. Discontinuation rates within eight weeks due to adverse effects were 9% among those who received personalized prescribing and 16% among the usual care group.

The decision support tool was developed during the Personalising Antidepressant Treatment for Unipolar Depression Combining Individual Choices, Risks and Big Data (PETRUSHKA) project. The researchers . . .

Want To Read More? Log In Or Become A Paid Member
Resource Available For Paid OPEN MINDS Circle Members Only
Not a paid member? Don't miss out! Sign up today and receive unlimited organizational access to all OPEN MINDS strategic advice, market intelligence, and management best practices – over 250,000 resources!
Log In
If you are already a paid member, log in to your account to access this resource and more. If you are a free member, you will need to upgrade to a paid membership before accessing this resource.

Become A Paid Member
If you are not yet a paid member, learn more about the OPEN MINDS Circle Market Intelligence Service Membership on our website, reach out to our team at info@openminds.com, or call us at 877-350-6463.

International